A novel type of familial transthyretin amyloidosis, ATTR Asn124Ser, with co-localization of κ light chains

References

• Westermark P, Benson M D, Buxbaum J N, Cohen A S, Frangione B, Ikeda S, Masters C L, Merlini G, Saraiva M J, Sipe J D. Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid: J Protein Folding Disord 2005; 12: 1–4
   PubMed Web of Science ®Google Scholar
• Rochet J C, Lansbury P T, Jr. Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol 2000; 10: 60–68
   PubMed Web of Science ®Google Scholar
• Connors L H, Lim A, Prokaeva T, Roskens V A, Costello C E. Tabulation of human transthyretin (TTR) variants 2003. Amyloid: J Protein Folding Disord 2003; 10: 160–184
   PubMed Web of Science ®Google Scholar
• Holmgren G, Costa P M, Andersson C, Asplund K, Steen L, Beckman L, Nylander P O, Teixeira A, Saraiva M J, Costa P P. Geographical distribution of TTR met30 carriers in northern Sweden: discrepancy between carrier frequency and prevalence rate. J Med Genet 1994; 31: 351–354
   PubMed Web of Science ®Google Scholar
• Alves I L, Altland K, Almeida M R, Winter P, Saraiva M J. Screening and biochemical characterization of transthyretin variants in the Portuguese population. Hum Mutat 1997; 9: 226–233
   PubMed Web of Science ®Google Scholar
• Araki S. Type I familial amyloidotic polyneuropathy. No To Hattatsu 1984; 16: 92–100
   PubMedGoogle Scholar
• Palacios S A, Bittencourt P L, Cancado E L, Farias A Q, Massarollo P C, Mies S, Kalil J, Goldberg A C. Familial amyloidotic polyneuropathy type 1 in Brazil is associated with the transthyretin Val30Met variant. Amyloid: Int J Exp Clin Invest 1999; 6: 289–291
   PubMed Web of Science ®Google Scholar
• Munar-Ques M, Saraiva M J, Viader-Farre C, Zabay-Becerril J M, Mulet-Ferrer J. Genetic epidemiology of familial amyloid polyneuropathy in the Balearic Islands (Spain). Amyloid: J Protein Folding Disord 2005; 12: 54–61
   PubMed Web of Science ®Google Scholar
• Suhr O B, Svendsen I H, Andersson R, Danielsson A, Holmgren G, Ranløv P J. Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med 2003; 254: 225–235
   PubMed Web of Science ®Google Scholar
• Westermark P, Sletten K, Johansson B, Cornwell G G, 3rd. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc Natl Acad Sci USA 1990; 87: 2843–2845
   PubMed Web of Science ®Google Scholar
• Bergström J, Gustavsson Å, Hellman U, Sletten K, Murphy C L, Weiss D T, Solomon A, Olofsson B O, Westermark P. Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 2005; 206: 224–232
   PubMed Web of Science ®Google Scholar
• Cornwell G G, 3rd, Murdoch W L, Kyle R A, Westermark P, Pitkänen P. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med 1983; 75: 618–623
   PubMed Web of Science ®Google Scholar
• Hagen G A, Elliott W J. Transport of thyroid hormones in serum and cerebrospinal fluid. J Clin Endocrinol Metab 1973; 37: 415–422
   PubMed Web of Science ®Google Scholar
• Kanai M, Raz A, Goodman D S. Retinol-binding protein: the transport protein for vitamin A in human plasma. J Clin Invest 1968; 47: 2025–2044
   PubMed Web of Science ®Google Scholar
• Bellotti V, Mangione P, Merlini G. Review: immunoglobulin light chain amyloidosis – the archetype of structural and pathogenic variability. J Struct Biol 2000; 130: 280–289
   PubMed Web of Science ®Google Scholar
• Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med 2004; 255: 159–178
   PubMed Web of Science ®Google Scholar
• Isobe T, Osserman E F. Patterns of amyloidosis and their association with plasma-cell dyscrasia, monoclonal immunoglobulins and Bence-Jones proteins. N Engl J Med 1974; 290: 473–477
   PubMed Web of Science ®Google Scholar
• Kyle R A, Gertz M A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995; 32: 45–59
   PubMed Web of Science ®Google Scholar
• Obici L, Perfetti V, Palladini G, Moratti R, Merlini G. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta 2005; 1753: 11–22
   PubMed Web of Science ®Google Scholar
• Patrosso M C, Salvi F, De Grandis D, Vezzoni P, Jacobson D R, Ferlini A. Novel transthyretin missense mutation (Thr34) in an Italian family with hereditary amyloidosis. Am J Med Genet 1998; 77: 135–138
   PubMed Web of Science ®Google Scholar
• Gaffney E. Congo red method for amyloid. Laboratory Methods in Histopathology, E B Prophet, E Mills, J B Arrington, L H Sobin. Armed Forces Institute of Pathology, Washington, DC 1992; 168
   Google Scholar
• Bergström J, Murphy C L, Weiss D T, Solomon A, Sletten K, Hellman U, Westermark P. Two different types of amyloid deposits – apolipoprotein A-IV and transthyretin – in a patient with systemic amyloidosis. Lab Invest 2004; 84: 981–988
   PubMed Web of Science ®Google Scholar
• Montagna P, Marchello L, Plasmati R, Ferlini A, Patrosso M C, Salvi F. Electromyographic findings in transthyretin (TTR)-related familial amyloid polyneuropathy (FAP). Electroencephalogr Clin Neurophysiol 1996; 101: 423–430
   PubMedGoogle Scholar
• Salvi F, Scaglione C, Michelucci R, Linke R P, Obici L, Ravani A, Rimessi P, Ferlini A, Meletti S, Cavallaro T, Tassinari C A, Martinelli P. Atypical familial motor neuropathy in patients with mutant TTR Ile68Leu. Amyloid: J Protein Folding Disord 2003; 10: 185–189
   PubMed Web of Science ®Google Scholar
• Salvi F, Pastorelli F, Plasmati R, Ferlini A, Grazi G L, Jovine E, Mascalchi M, Tassinari C A. Early onset aggressive hereditary amyloidosis: report of an Italian family with TTR Arg47 mutation. Neurol Sci 2005; 26: 140–142
   PubMed Web of Science ®Google Scholar
• Quintas A, Saraiva M J, Brito R M. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution. FEBS Lett 1997; 418: 297–300
   PubMed Web of Science ®Google Scholar
• Jiang X, Buxbaum J N, Kelly J W. The V122I cardiomyopathy variant of transthyretin increases the velocity of rate-limiting tetramer dissociation, resulting in accelerated amyloidosis. Proc Natl Acad Sci USA 2001; 98: 14943–14948
   PubMed Web of Science ®Google Scholar
• Hammarström P, Jiang X, Hurshman A R, Powers E T, Kelly J W. Sequence-dependent denaturation energetics: a major determinant in amyloid disease diversity. Proc Natl Acad Sci USA 2002; 4(99 Suppl)16427–16432
   Google Scholar
• Eneqvist T, Sauer-Eriksson A E. Structural distribution of mutations associated with familial amyloidotic polyneuropathy in human transthyretin. Amyloid: J Protein Folding Disord 2001; 8: 149–168
   PubMed Web of Science ®Google Scholar
• Hamilton J A, Benson M D. Transthyretin: a review from a structural perspective. Cell Mol Life Sci 2001; 58: 1491–1521
   PubMed Web of Science ®Google Scholar
• G Grateu, Kyle, R A, Skinner, M. Codeposition of transthyretin and immunoglobulin lambda chain in senile systemic (ATTR) amyloidosis. The Xth International Symposium on Amyloidosis; 2004 April 18 – 22; Tours. CRC Press, Washington, DC 1992; 332–333
   Google Scholar
• de Sousa M M, Vital C, Ostler D, Fernandes R, Pouget-Abadie J, Carles D, Saraiva M J. Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis. Am J Pathol 2000; 156: 1911–1917
   PubMed Web of Science ®Google Scholar